Bioinformatic identification of novel lncRNAs potentially involved in the pathogenesis of gastric cancer: an in silico approach

Gastric cancer is one of the most important cancers associated with mortality in the world. Clinically, gastric cancer is detected at advanced stages, so it is necessary that be diagnosed at early stages by non-invasive methods, before metastasis. lncRNAs are RNA molecules approximately 200 nucleotides that play a role in regulating of important cellular processes including proliferation, differentiation, apoptosis, and invasion. Thus, changes in their expression levels can lead to diseases such as cancer. With the advancement of new technologies such as next generation sequencing, has facilitated the expression profiling of molecules involved in various diseases, including cancers.In this research, using bioinformatics databases such as MiTranscriptome, Cancer RNA-Seq Nexus, OncoLnc, GeneCards, LncRNAWiki, Lnc2Cancer, GCGene, we retrieved a number of novel-predicted lncRNAs that participated in the pathogenesis of gastric cancer. By reviewing these novel lncRNAs in text databases such as PubMed and Octopus, separated lncRNAs that are not yet approved experimentally. The result is two separate lists from lncRNAs, inclusive lncRNAs that have been validated to be involved in gastric cancer such as MALAT1, PVT1, GAS5, TINCR , ZFAS1, TUSC7, MIR22HG, and a list from novel-predicted lncRNAs, such as MFI2-AS1, HHIP-AS1, ST7-AS1, C1RL-AS1, USP3-AS1, ZNF790-AS1, MORC2-AS1, OSER1-AS1, RPL34-AS1, DDX11-AS1, ARHGAP5-AS1, RSBN1L-AS1, COX10-AS1, PCBP1-AS1, LINC00883, LOC541471, LINC00920. With experimental validation of the involvement of predicted novel lncRNAs in gastric cancer can be used as non-invasive biomarkers for early diagnosis and targeted treatment of gastric cancer.

Keywords:

Gastric Cancer , lncRNAs , Bioinformatics , Next Generation Sequencing